Cargando…

Multi-country clinical practice patterns, including use of biomarkers, among physicians’ treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC)

BACKGROUND: Intravesical bacillus Calmette-Guérin (BCG) fails in a considerable proportion of non-muscle invasive bladder cancer (NMIBC) patients despite treatment per recommended protocol. This real-world study aimed to understand the current patterns of treatment and disease management for the bro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Broughton, Edward I., Gooden, Kyna M., Mycock, Katie L., Rajkovic, Ivana, Taylor-Stokes, Gavin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8882282/ https://www.ncbi.nlm.nih.gov/pubmed/35219307 http://dx.doi.org/10.1186/s12894-022-00959-z

Ejemplares similares

Treatment and disease management patterns for bacillus Calmette-Guérin unresponsive nonmuscle invasive bladder cancer in North America, Europe and Asia: A real-world data analysis
por: Broughton, Edward I., et al.
Publicado: (2022)

Elicitation of Health State Utilities Associated with Progression from Bacillus Calmette-Guerin (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC)
por: Cooper, Owen Alan Edwards, et al.
Publicado: (2023)

Once BCG Unresponsive, Always BCG Unresponsive: An Open Letter to the FDA to Enhance Recruitment into Clinical Trials in Bladder Cancer
por: Kamat, Ashish M., et al.
Publicado: (2017)

Outcomes of BCG Induction in High-Risk Non-Muscle-Invasive Bladder Cancer Patients (NMIBC): A Retrospective Cohort Study
por: Pirzada, Muhammad T, et al.
Publicado: (2017)

Intravesical ALT-803 for BCG-unresponsive Bladder Cancer – A Case Report
por: Huang, Jeffrey, et al.
Publicado: (2017)

Compared Efficacy of Adjuvant Intravesical BCG-TICE vs. BCG-RIVM for High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC): A Propensity Score Matched Analysis
por: Del Giudice, Francesco, et al.
Publicado: (2022)

BCG instillation versus radical cystectomy for high-risk NMIBC with squamous/glandular histologic variants
por: Suh, Jungyo, et al.
Publicado: (2019)

Hyperthermic Intravesical Chemotherapy for BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients
por: de Jong, Joep J., et al.
Publicado: (2018)

Novel intravesical bacterial immunotherapy induces rejection of BCG-unresponsive established bladder tumors
por: Moreo, Eduardo, et al.
Publicado: (2022)

Phase I study of patients with non-muscle invasive bladder cancer (NMIBC) treated with vesigenurtacel-L (HS-410) after Bacillus Calmette-Guérin (BCG)
por: Steinberg, Gary, et al.
Publicado: (2015)

Editorial: New frontiers in “bladder sparing” treatments for high risk NMIBC
por: Hurle, Rodolfo, et al.
Publicado: (2023)

A Phase I/II study of vesigenurtacel-l (hs-410) or placebo in combination with Bacillus Calmette-Guérin (BCG) in patients with non-muscle invasive bladder cancer (NMIBC)
por: Steinberg, Gary D, et al.
Publicado: (2014)

Bacillus Calmette-Guérin (BCG) Treatment Failures with Non-Muscle Invasive Bladder Cancer: A Data-Driven Definition for BCG Unresponsive Disease
por: Steinberg, Ryan L., et al.
Publicado: (2016)

The bladder microbiome of NMIBC and MIBC patients revealed by 2bRAD-M
por: Sun, Jian-Xuan, et al.
Publicado: (2023)

BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer: Current Treatment Landscape and Novel Emerging Molecular Targets
por: Claps, Francesco, et al.
Publicado: (2023)

Intravesical ICIs to reduce toxicity in NMIBC
por: Masone, Maria Chiara
Publicado: (2022)

Letter to the Editor: Bacillus Calmette-Guerin (BCG) Treatment Failures with Non-Muscle Invasive Bladder Cancer: A Data-Driven Definition for BCG Unresponsive Disease
por: Li, Roger, et al.
Publicado: (2017)

Gene mutation detection of urinary sediment cells for NMIBC early diagnose and prediction of NMIBC relapse after surgery
por: Zhu, Feng, et al.
Publicado: (2019)

BCG-unresponsive high-grade non-muscle invasive bladder cancer: what does the practicing urologist need to know?
por: Lebacle, Cedric, et al.
Publicado: (2021)

Real-World Palbociclib Use in HR+/HER2− Advanced Breast Cancer in Canada: The IRIS Study
por: Mycock, Katie, et al.
Publicado: (2021)

From Interferon to Checkpoint Inhibition Therapy—A Systematic Review of New Immune-Modulating Agents in Bacillus Calmette–Guérin (BCG) Refractory Non-Muscle-Invasive Bladder Cancer (NMIBC)
por: Deininger, Susanne, et al.
Publicado: (2022)

Immune responses against SARS-CoV-2 wildtype in unvaccinated patients with high-risk NMIBC undergoing intravesical BCG therapy
por: Pichler, R., et al.
Publicado: (2023)

Bacillus Calmette-Guérin (BCG) Treatment Failures in Non-Muscle Invasive Bladder Cancer: What Truly Constitutes Unresponsive Disease
por: Steinberg, Ryan L., et al.
Publicado: (2015)

Prostatic urethra recurrence after transurethral resection of bladder tumor (TURBT) for non‐muscle‐invasive bladder cancer (NMIBC)
por: Bilim, Vladimir, et al.
Publicado: (2022)

Treatment efficacy and tolerability of intravesical Bacillus Calmette-Guerin (BCG) - RIVM strain: induction and maintenance protocol in high grade and recurrent low grade non-muscle invasive bladder cancer (NMIBC)
por: Farah, Naim B, et al.
Publicado: (2014)

Conservative treatment for high-risk NMIBC failing BCG treatment: who benefits from adding electromotive drug administration (EMDA) of mitomycin C (MMC) to a second BCG induction cycle?
por: Busetto, Gian Maria, et al.
Publicado: (2023)

Interruption of BCG Therapy for NMIBC During COVID-19 Crisis, Dilemma in Its Continuation: a Review of Available Evidence and Suggested Management Strategies
por: Tosh, Jyoti Mohan, et al.
Publicado: (2023)

Intravesical gemcitabine as bladder‐preserving treatment for BCG unresponsive non‐muscle‐invasive bladder cancer. Results from a single‐arm, open‐label study
por: Hurle, Rodolfo, et al.
Publicado: (2020)

Association of De Ritis ratio with oncological outcomes in patients with non-muscle invasive bladder cancer (NMIBC)
por: Laukhtina, Ekaterina, et al.
Publicado: (2020)

Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscleinvasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette- Guérin (BCG): results of an international individual patient data survey (IPDS)
por: Witjes, J Alfred, et al.
Publicado: (2013)

Effects of intravesical BCG maintenance therapy duration on recurrence rate in high-risk non-muscle invasive bladder cancer (NMIBC): Systematic review and network meta-analysis according to EAU COVID-19 recommendations
por: Moon, Young Joon, et al.
Publicado: (2022)

Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced or Metastatic Breast Cancer in Argentina: The IRIS Study
por: Waller, John, et al.
Publicado: (2019)

Efficacy of Mycobacterium Phlei Cell Wall-Nucleic Acid Complex (MCNA) in BCG-Unresponsive Patients
por: Li, Roger, et al.
Publicado: (2017)

Required efficacy for novel therapies in BCG‐unresponsive non‐muscle invasive bladder cancer: Do current recommendations really reflect clinically meaningful outcomes?
por: Wettstein, Marian S., et al.
Publicado: (2020)

Efficacy of Different Bacillus of Calmette-Guérin (BCG) Strains on Recurrence Rates among Intermediate/High-Risk Non-Muscle Invasive Bladder Cancers (NMIBCs): Single-Arm Study Systematic Review, Cumulative and Network Meta-Analysis
por: Del Giudice, Francesco, et al.
Publicado: (2023)

The Evaluation of the Risk Factors for Non-Muscle Invasive Bladder Cancer (NMIBC) Recurrence after Transurethral Resection (TURBt) in Chinese Population
por: Liu, Shenghua, et al.
Publicado: (2015)

Validation and reliability of the Dutch version of the EORTC QLQ-NMIBC24 Questionnaire Module for patients with non-muscle-invasive bladder cancer
por: Ripping, Theodora M., et al.
Publicado: (2021)

NBI cystoscopy and bipolar electrosurgery in NMIBC management – An overview of daily practice
por: Geavlete, B, et al.
Publicado: (2013)

BCG in Bladder Cancer Immunotherapy
por: Jiang, Song, et al.
Publicado: (2022)

Systemic BCG‐osis following intravesical BCG instillation for bladder carcinoma
por: Liaw, Frank, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_dtpokulub2qr8tmk2jgs3q78th